#Repurposing fidaxomicin, a macrocyclic antibiotic against C. difficile, to resensitize treatment-resistant HSC-derived MLL-AML cells expressing multispecific anion transporter ABCC3 toward standard chemotherapeutic drugs. https://t.co/5U9NTKl5vj
FDA tarafından onaylanmış bir diyare (ishal) ilacının kemoterapiye direnci azaltarak, ilaçların lösemi üzerindeki etkisini arttırabileceği ortaya konuldu. 🔗 https://t.co/RIKVA0O8XL https://t.co/sVXjRbD1r2
'Inhibition of ABCC3 by shRNA-mediated knockdown or with small-molecule inhibitor fidaxomicin, currently used for diarrhea associated with Clostridium difficile infection, effectively resensitized HSC-derived MLL-AML toward standard chemotherapeutic drugs'
“By combining prospective disease modeling using highly purified human hematopoietic stem or progenitor cells with retrospective deconvolution study of LSCs from primary patient samples, we identified human HSCs and CMPs as two distinctive origins of human